Invest Properly During the Reopening With AI

This article was written by Gabriel Plat, a Financial Analyst at I Know First.

Summary:

  • High vaccination rates are speeding up the reopening phases across the globe;
  • Stocks and indexes fell due to uncertainty, but are ready to bounce back;
  • Tourism and entertainment sectors could be good investment opportunities;
  • I Know First AI-powered algorithm can improve your portfolio.

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

Investment under the Coronavirus Pressure

Sergey Okun  This "Investment under the Coronavirus Pressure" article was written by Sergey Okun – Senior Financial Analyst, I Know First, Ph.D. in Economics.

Summary:

  • The emergence the Omicron variant has significantly increased volatility in the market
  • The reaction of FED to Omicron is unclear now taking into account the inflation threat The annual i
  • The annual inflation rate in the US surged to 6.2% in October 2021

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

The Coronavirus Package Content

The main focus of the Coronavirus package is to cover the assets that may be affected by the coronavirus with the biggest financial exposures and it includes assets such as gold and relevant commodities, biotech companies’ stocks, pharmaceutical companies’ stocks, semiconductors, and technological sectors stocks and more. The Coronavirus package contents 142 tickers on December 2nd, 2021

I Know First Weekly Review Algorithmic Performance: June 23rd, 2021


I Know First Weekly Newsletter
Investment Selection Using AI Predictive Algorithm
June 23, 2021

Read The Full Newsletter

Coronavirus Stock Market: New Opportunities Rise With the Vaccine

This article was written by Gabriel Plat, a Financial Analyst at I Know First.

Summary:

  • The vaccine is closer than we thought. Pfizer and BioNTech plan to distribute it by 2021;
  • AHT grew 228% in 3 days, indicating opportunities that might be available when the pandemic is over;
  • The entertainment and flight industries can be a huge opportunity to look at;
  • I Know First algorithm is the best way to maximize your profit amid these opportunities.

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

Aggressive Stocks Predictions: Real-life Success Story Amid Market Chaos

Summary:

  • Market volatility and chaos pushes investors to either take greater risks or go into safe assets zone in 2020
  • Aggressive stocks outstand from the market providing higher returns far above the S&P 500
  • AI-powered stock predictive algorithm enabled I Know First client to create aggressive stocks portfolios to outperform market 7 times within 3 months

How Risky is the Stock Market Nowadays?

aggressive stocks predictions

Have you ever imagined 2020 to be that risky and aggressive stocks strategies to become popular more than ever before? Looking back to January 2020, many market players now are not feeling well about diversification or following the Wall street gurus’ strategies, like Warren Buffet, who invested for the long term into ‘real’ economy sectors. While the whole world was going into closures and various economy sectors were seizing operations as the global pandemic was gaining momentum in March, we at I Know First we perfecting our AI predictive algorithm to identify the Coronavirus

Read More

I Know First Weekly Review Algorithmic Performance: August 20th, 2020


I Know First Weekly Newsletter
Investment Selection Using AI Predictive Algorithm
August 20, 2020

">

Read The Full Newsletter

DVAX Stock Forecast: High-risk Player Amidst Potential COVID Vaccine

The Tesla stock forecast was written by Hugh Camiener, Analyst at I Know First. Bachelor of Arts candidate at Columbia University.

Summary

  • Dynavax is a commercial state biopharmaceutical company which develops and commercializes vaccines..
  • Dynavax has an FDA approval on their Hepatitis B vaccine, and they have partnered with Sinovac in developing a vaccine for COVID. 
  • The pandemic has caused a significant decline in Dynavax’s revenue, with their net product revenue falling 71% in comparison to Q2 last year.
  • Dynavax’s vaccine partnership with Sinovac has shown positive signs in phase 1 and phase 2 of testing, and their vaccine will be entering phase 3 in Brazil.
  • There is a large amount of volatility in the biopharmaceutical industry; amidst Russia’s self-proclaimed vaccine, Dynavax’s stock fell 9.7%.
  • Dynavax stock forecast remains a high-risk, high reward option..

Read The Full Premium Article

Subscribe to receive exclusive PREMIUM content Here
Pages:1234»